Clenpiq (Ferring Pharmaceuticals), an oral solution for cleansing of the colon in adults undergoing a colonoscopy, has been approved for market by the Food and Drug Administration (FDA).
The dual-acting solution consists of sodium picosulfate, magnesium oxide, and anhydrous citric acid. Sodium picosulfate is a stimulant laxative, and magnesium oxide and anhydrous citric form magnesium citrate, an osmotic laxative. Upon launch, it will become the only FDA-approved colonoscopy prep that is “ready-to-drink”.
Clenpiq is contraindicated in patients with severe renal impairment, gastrointestinal obstruction or ileus, bowel perforation, toxic colitis or toxic megacolon, gastric retention, or in patients with a known hypersensitivity to any of its ingredients.
“Having a ready-to-drink, low volume colonoscopy prep in a pre-mixed oral solution is an excellent start to prepare patients for this important procedure,” said Dr. Edward Brettholz, Clinical Assistant Professor of Medicine, NYU School of Medicine.
Clenpiq solution is cranberry-flavored and the Company says it is expected to be available in Q1 of 2018.
For more information call (888) 337-7464 or visit FerringUSA.com.